1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1690
  5. Art Unit 1691
  6. Examiner Lewis

Examiner Lewis Patrick T

1691-LEWIS-PATRICK-T

Employment Information

Art Unit:1691 — Drug, bio-affecting and body treating compositions
Group:1690 — Organometallics & Industrial Chemistry and Carbohydrate Chemistry
Classes: 514 — Drug, bio-affecting and body treating compositions
536 — Organic compounds -- part of the class 532-570 series
424 — Drug, bio-affecting and body treating compositions
435 — Chemistry: molecular biology and microbiology
546 — Organic compounds -- part of the class 532-570 series
530 — Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
549 — Organic compounds -- part of the class 532-570 series
600 — Surgery
Phone:(571) 272-0655
Email:patrick.lewis@uspto.gov
Location:VA 22314
Title:Pat Examnr Gen Chem
Service:24 years
Grade:GS-14

Grant Rate and Difficulty Ranking

54
3-Year Grant rate: 75% over 420 cases
Difficulty: Medium
Difficulty Percentile: 54th

With Examiner Lewis, you have a 75% chance of getting an issued patent by 3 years after the first office action. Examiner Lewis is a medium examiner and in the 54th percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Lewis, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1691

Examiner Lewis's grant rate is lower than that of Art Unit 1691 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Lewis 1.4
Art Unit 1691 1.1

Interview Benefit

Grant Rate without Interview

Examiner Lewis has granted 268 of 364 cases without any applicant-requested interviews for a grant rate of 74%.

Grant Rate with Interview

Examiner Lewis has granted 46 of 56 cases with at least one applicant-requested interview for a grant rate of 82%.

Interview Benefit

With Examiner Lewis, conducting an interview increases your chance of getting a patent granted by 11%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
18833747 Antiviral Prodrugs, Intermediate-And Long-Acting Formulations And Methods Rejection information available with a Premium Stats subscription. See our pricing. Patented View
18160925 Indodicarbocyanine Phosphoramidites With Bathochromically Shifted Absorption And Emission, And Tunable Hydrophobicity Patented View
18001859 Compounds For The Treatment Of Viral Infections Abandoned View
18143675 Magnetic Bead Based Nucleic Acid Extraction System Patented View
17763127 Senolytic And Antiinflammatory Prodrugs And Methods Of Use Thereof Patented View
17998644 Compositions And Methods For Treating Viral Infections Abandoned View
17441087 Stable Formulations Of Cyclic Dinucleotide Sting Agonist Compounds And Methods Of Use Thereof Abandoned View
19193361 Nicotinamide Riboside And Derivatives Thereof In Intravenous Formulations And Methods Of Use Thereof Patented View
17923784 Synthesis Of Fluorinated Nucleotides Patented View
18184288 N4-Hydroxycytidine And Derivatives And Anti-Viral Uses Related Thereto Patented View
18455539 Betalain Compositions And Methods Therefor Patented View
17594287 Methods And Compositions For Irreversible Enzyme Inhibition Patented View
17907160 Compositions And Methods Containing N-Acetylcystein And Nicotinamide Riboside For Prevention And Treatment Of Neurological Diseases And Conditions Patented View
17614055 Compositions And Methods For Treating Metabolic Disease Patented View
17780390 Mixture Of Hmos For Improving The Microbiota Of Pregnant Women Patented View
19196922 Azithromycin Premix Formulation And Product, Methods Of Preparing Same, And Methods Of Using Same Patented View
17927589 Therapeutic Agent For An Rna Virus Infection Comprising A Combination Of A Pyrazine Derivative And A Thiopurine Derivative Abandoned View
17918964 Method For Treating Arenaviridae Infections Abandoned View
18191901 Inorganic Salts Of Nicotinic Acid Mononucleotide As Anti-Aging Agents Abandoned View
17927478 Use Of Nmn To Reduce Immunodepression And Immunosenescence Abandoned View
17767825 Method For Producing Nucleic Acid Oligomers Patented View
17770520 Glycoside Compound, Amidite Compound, And Production Method For Polynucleotide Using Said Compounds Patented View
18583315 Method Of Preventing Of Systemic-To-Pulmonary-Artery Shunt Thrombosis Patented View
18030129 Parenteral Nutrition Formulation And Methods Of Preparation Thereof Patented View
17915783 Compositions Incorporating Sulfated Polysaccharides For Inhibiting Sars-Cov-2 Abandoned View
18519667 Compositions And Methods Using At Least One Glycine Or Derivative Thereof, At Least One N-Acetylcysteine Or Derivative Thereof, And At Least One Nicotinamide Riboside Or Nad+ Precursor Patented View
17595565 Recycle Content Cellulose Ester Patented View
17619081 Novel Compound Derived From Watermelon, And Composition Using Same Patented View
17905210 Compositions And Methods Containing Reduced Nicotinamide Riboside For Prevention And Treatment Of Cardiovascular Diseases And Conditions Abandoned View
17905262 Compositions And Methods Containing Reduced Nicotinamide Riboside For Prevention And Treatment Of Neurological Diseases And Conditions Abandoned View
18516416 Nicotinamide Mononucleotide Derivatives And Their Uses Patented View
17636794 A Prodrug Platform Useful To Deliver Amines, Amides And Phenols Patented View
17753150 Thickeners And Nutritional Products To Promote Safe Swallowing For Individuals With Dysphagia And Methods Of Making And Using Same Patented View
17552750 Nucleic Acid Conjugates And Uses Thereof Patented View
17641083 Use Of Dnmt Inhibitor Patented View
17995793 Methods, Compositions, And Dosing Regimens For Treatment Of Sars-Cov-2 Infections Patented View
17297259 Tetramolecular Parallel G-Quadruplex-Forming Hydrophobically Modified Oligonucleotides Patented View
17583378 Anti-Viral And Anti-Tumoral Compounds Patented View
19215054 Advantageous Anti-Hcv Combination Therapy Patented View
18516459 Modulators Of 5'-Nucleotidase, Ecto And The Use Thereof Patented View
17635140 Modified Nucleoside And Synthesis Method Therefor Abandoned View
17620545 Azacitidine In Combination With Venetoclax, Gilteritinib, Midostaurin Or Other Compounds For Treating Leukemia Or Myelodysplastic Syndrome Patented View
17638537 Sting Inhibitors And Their Therapeutic Uses Patented View
17363983 5'-Cyclo-Phosphonate Modified Nucleotides Patented View
17613197 Formulations Of Cyclic Macromolecule-Based Nanoparticles Encapsulating Small Molecules Patented View
18394488 Methods For Treatment Of Viral Infections Abandoned View
18028080 Nicotinamide Mononucleotide Derivatives And Use Thereof In The Treatment And Prevention Of A Red Blood Cell Disorder Patented View
17427134 5'-Modified Nucleoside And Nucleotide Using Same Patented View
17777149 Nucleic Acid Separation Method, Detection Method, Nucleic Acid Purification Column And Method Of Producing Same Patented View
17625592 Enhancing The Antiviral Efficacy Of Rna Virus Inhibition By Combination With Modulators Of Pyrimidine Metabolism Abandoned View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.